Development of elastin-like polypeptide for targeted specific gene delivery in vivo (2020)
Sequence: Tat-(AP1)x4-ELP (VPGXG)x48
| Experiment Id | EXP000507 |
|---|---|
| Paper | Development of elastin-like polypeptide for targeted specific gene delivery in vivo |
| Peptide | Tat-A4V48 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | 250 µg/kg |
| Mixing Ratio | 1:20 (siRNA:ELP) |
| Formulation Format | ELP–siRNA nanocomplex |
| Formulation Components | ELP ± Tat ± AP1 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | 4T1-luc allograft mice |
| Administration Route | intravenous |
| Output Type | in vivo luciferase silencing |
| Output Value | |
| Output Units | |
| Output Notes | Robust silencing only for Tat-A1E28 and Tat-A4V48 |
| Toxicity Notes | no major toxicity observed |
| Curation Notes |